Alicia McElhaney

Recent Articles By The Author

Mylan Expands EpiPen Recall

Mylan Expands EpiPen Recall

The company fell nearly 2% after announcing the news this weekend.

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

The animal health company combines with its former owner in a reverse merger.

Here Are Some of the Top Health Care Stocks in the First Quarter

Here Are Some of the Top Health Care Stocks in the First Quarter

Illumina, Centene, Community Health, Incyte and Vertex were among the healthcare stocks that did well in the first quarter.

Ackman Reflects on His Valeant Investment

Ackman Reflects on His Valeant Investment

The Pershing Square manager also holds a stake in Chipotle and used to be invested in JCPenney and Canadian Pacific Railway. Here are some of his most contentious investments.

Ackman Says He's Sorry For Valeant Investment

Ackman Says He's Sorry For Valeant Investment

The Pershing Square manager apologized to clients in his annual letter.

FDA Rejection of Mylan Generic Adds to its Woes

FDA Rejection of Mylan Generic Adds to its Woes

The company's shares were falling again on Wednesday, this time on the news that its initial application for an anti-asthma generic had been rejected by the FDA.

Valeant's Banks Extend a Lifeline

Valeant's Banks Extend a Lifeline

The deal helps the company manage its $31 billion debt load, sending the shares up nearly 4% midday Wednesday.

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

Mylan Hires Former SEC Commissioner for Chief Legal Officer Position

The company could be gearing up for multiple challenges on the D.C. front, analysts say.

Former Valeant CEO Files Suit Against the Company

Former Valeant CEO Files Suit Against the Company

Mike Pearson is alleging that Valeant has refused to pay him for the three million shares he is owed.

Impax Gains 38% On CEO Appointment, Talk of Sale

Impax Gains 38% On CEO Appointment, Talk of Sale

The company hired Paul Bisaro, former chairman at Allergan, to become CEO as Morgan Stanley helps explore alternatives, including a sale.